Inter Pharma PCL (BKK:IP) LT-Debt-to-Total-Asset : 0.08 (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Inter Pharma PCL LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Inter Pharma PCL's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.08.

Inter Pharma PCL's long-term debt to total assets ratio declined from Dec. 2023 (0.09) to Dec. 2024 (0.08). It may suggest that Inter Pharma PCL is progressively becoming less dependent on debt to grow their business.

Inter Pharma PCL LT-Debt-to-Total-Asset Historical Data

The historical data trend for Inter Pharma PCL's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inter Pharma PCL LT-Debt-to-Total-Asset Chart

Inter Pharma PCL Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.12

0.14

0.13

0.09

0.08

Inter Pharma PCL Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.09	0.08	0.08	0.08	0.08

Inter Pharma PCL LT-Debt-to-Total-Asset Calculation

Inter Pharma PCL's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	232.691	/	3020.562
	=	0.08

Inter Pharma PCL's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	232.691	/	3020.562
	=	0.08

Inter Pharma PCL (BKK:IP) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Inter Pharma PCL LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Inter Pharma PCL's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Inter Pharma PCL Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inter Pharma PCL (BKK:IP) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Silom Road, 140/9 ITF Tower 9th Floor, Suriyawongse, Bangrak, Bangkok, THA, 10500

Website

https://www.interpharma.co.th

Inter Pharma PCL is a biopharmaceutical company. It is engaged in the import, manufacture and distribution of drug, and dietary supplement products for humans and animals. It offers products related to Wellness and Anti-aging, Aesthetics, Diagnostics, Vitamins, and other products. The company operates in three reportable segments Human healthcare, Animal Healthcare, and Hospital and clinics in Thailand. Key revenue is derived from the Human healthcare segment.